Long Read Sequencing Market Trends

Growth Drivers

• Technology advancements in genomic analysis: With the growing amount of long read sequencing data, cloud platforms with AI algorithms are becoming crucial in the healthcare sector. The NIH's All of Us program in 2024 initiated a collaboration with Amazon Web Services to host long read genomic datasets for national-scale analysis. AI is now facilitating fast variant annotation, quality scoring, and clinical report generation essential for real-time oncology and infectious disease decision-making. These technologies enhance access, turnaround time, and cost, further increasing demand throughout hospitals and public health labs.
• Manufacturers' strategies and innovations: Many leading companies are adopting innovative strategies in their firms to broaden long read sequencing footprint. For example, Oxford Nanopore Technologies has collaborated with the UK's National Health Service to deploy LRS in more than 45 regional hospitals in 2024. This move is specially addressed to expand real-time sequencing for cancer patients and infectious diseases. This collaboration has surged the long read sequencing market share by 18.4% in the UK. Similarly, Pacific Biosciences introduced Revio, a 2023 high-throughput LRS platform, reducing per-genome costs by 60.6% and boosting worldwide clinical interest. Strategic partnerships are a major force behind increased adoption and access.
• Rising patient volume in rare disease genomics: In Europe, long read sequencing of diseases, particularly rare genetic disorders, is growing rapidly. As per the European Organization for Rare Diseases report, in Germany, nearly 1.6 million individuals were living with an undiagnosed rare disease in 2025, up 14.5% over the past decade. Long read sequencing is particularly well adapted for diagnosing diseases with big structural variants, including muscular dystrophy and Huntington's disease. Further, with rising clinical adoption and expanding national genomics initiatives, the patient population for long read applications will increase substantially throughout North America and Europe.

Historical Patient Growth Analysis: Foundation for Future Market Expansion

Historical Patient Growth (2010-2020)

Sources: NIH, BMBF, Inserm, HAS, FEDER, Genomics Health Futures Mission, AMED, ICMR, CAS

Manufacturer Strategies Shaping Market Expansion

Revenue Opportunities for Manufacturers

Sources: Genome, Genomics England, AHRQ, MOST

Challenges

• Awareness gaps in genomics sequencing adoption: Nearly 38.5% of U.S. adults were aware of the advantages of genomic sequencing in preventive medicine, according to a 2022 CDC survey. In France and Spain, where there are no early screening programs also the adoption of LRS tools for cancer and rare diseases has also been delayed. Companies like Illumina have introduced awareness campaigns through public hospitals, but their reach remains limited to urban areas. Responding, a number of EU-supported programs, such as the 1.3+ million genomes initiative, are attempting to expand public education and genomic literacy. Moreover, collaborations between biotech companies and national healthcare systems are developing to bring about the integration of long read sequencing into routine diagnostic pipelines.